LCS
IMRX icon

Levin Capital Strategies’s Immuneering IMRX Stock Holding History

Levin Capital Strategies’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.07M Buy
414,000
+404,000
+4,040% +$2.04M 0.14% 107
2026
Q1 		$52.7K Buy
+10,000
New +$51.3K ﹤0.01% 229

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Levin Capital Strategies's IMRX Position: Q2 2026 in Review

Levin Capital Strategies increased its Immuneering (IMRX) stake by 4,040% in Q2 2026, buying an estimated $2.04M and bringing the position to 414,000 shares worth $2.07M. The position accounts for 0.14% of the portfolio, ranked #107.

Levin Capital Strategies first reported a position in IMRX in Q1 2026 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Levin Capital Strategies held 414,000 shares of Immuneering worth $2.07M as of Q2 2026.
  • Levin Capital Strategies bought 404,000 Immuneering shares in Q2 2026, an estimated $2.04M.
  • Immuneering made up 0.14% of Levin Capital Strategies's portfolio in Q2 2026, its #107 holding.
  • Levin Capital Strategies first reported a position in Immuneering in Q1 2026 and has held it in 2 quarters since.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Levin Capital Strategies's 13F filing for Q2 2026, filed 31 Jul 2026.